Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.24), $0.01 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $14.1 million versus the consensus estimate of $13.42 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Community Banks sells equipment finance unit for $1.9 billion
• Sharon AI surges premarket; New Oriental gains, Medline slips